Monday, October 5, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· March 25, 2026

Universal Display to Highlight OLED Emissive Layer Advances for Display Efficiency and Performance at ICDT 2026

View original at finance.yahoo.com
Universal Display to Highlight OLED Emissive Layer Advances for Display Efficiency and Performance at ICDT 2026 EWING, N.J., March 25, 2026--(BUSINESS WIRE)--Universal Display Corporation (UDC) (Nasdaq: OLED), a global leader in energy-efficient OLED technologies and materials, today announced its participation in and…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • As technology advances rapidly, AI proliferates, and displays play an even more central role in how people experience the world through their devices, energy efficiency is ever important

    60% confidence
  • PHOLED materials support efficiency gains across a broad range of device designs, reinforcing their role in unlocking the next generation of OLED-based products

    60% confidence
  • Display efficiency has become a critical enabler of innovation in the electronics ecosystem as energy availability increasingly defines what is possible across consumer products

    60% confidence
  • From microdisplays for VR to smartphones and laptops through to large-screen televisions, high-efficiency OLEDs are unlocking new opportunities and are foundational to the future of displays and consumer electronics

    60% confidence
  • PHOLED materials enable low-power-consumption OLED displays with excellent color performance and long operational lifetimes

    60% confidence
  • UDC materials and technologies form the core of the OLED emissive layer and help drive efficiency across a wide range of device architectures, including single-stack OLED, tandem structures, PSF, and new pixel designs

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com